To The Moon

For what its worth based on current prices, forget overvalued AI stocks the likes of PLTR , NVDA or AVGO Instead buy the dip in pharma counters like GSK and MRCK. This is the time to invest now if you have not added - both counters are favorites in hedgefunds lists because of their sure upside potential.  To add to that, GSK has received recent approvals and endorsements for new drug development. GSK announced the US Food and Drug Administration, FDA, has accepted the New Drug Application, NDA, for gepotidacin, an investigational, first-in-class oral antibiotic with a novel mechanism of action for the treatment of female adults and adolescents with uncomplicated urinary tract infections, uUTIs. The FDA has granted Priority Review for this application and assigned a Prescription D

Oic now I understand 

$ARM Holdings Ltd(ARM)$ is set to be the largest IPO since 2021. According to its latest filings, price will be between $47 and $51 per share, with 95.5 million shares being offered. This puts ARM's IPO valuation between $50 billion and $54 billion, lower than the $64 billion valuation when $Softbank Group Corp(SFTBY)$ optained the remaining 25% stake last month.It also confirms major tech companies, including $Apple(AAPL)$ , $Alphabet(GOOG)$ $Alphabet(GOOGL)$ $Advanced Micro Devices(AMD)$ $NVIDIA

$Novavax(NVAX)$  Is it the threat from the return of the new COVID virus makes traders punting on it❓If not why it goes up 14% today ❗❗❗🤔

For what its worth based on current prices, forget overvalued AI stocks the likes of PLTR , NVDA or AVGO Instead buy the dip in pharma counters like GSK and MRCK. This is the time to invest now if you have not added - both counters are favorites in hedgefunds lists because of their sure upside potential.  To add to that, GSK has received recent approvals and endorsements for new drug development. GSK announced the US Food and Drug Administration, FDA, has accepted the New Drug Application, NDA, for gepotidacin, an investigational, first-in-class oral antibiotic with a novel mechanism of action for the treatment of female adults and adolescents with uncomplicated urinary tract infections, uUTIs. The FDA has granted Priority Review for this application and assigned a Prescription D

Oic now I understand